Cannabidiol as an add-on drug improves QoL in epilepsy I AES


  • RSi Communications
L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano

Takeaway

  • Based upon preliminary analyses, cannabidiol (CBD) as an add-on drug for the treatment of pharmacoresistant epilepsy in a pediatric population does not appear to cause adverse effects involving cognition or adaptive function in patients who completed 1 year of treatment.

Why this matters

  • Caregivers reported an overall improvement in quality of life (QoL).

Study design

  • Participants (N=42) between the ages of 3 and 19 years with pharmacoresistant epilepsy were enrolled in an open label study of a pharmaceutical formulation of CBD (Epidiolex) as an add-on treatment of epilepsy by researchers at the University of Alabama at Birmingham.
  • In addition to assessing several baseline medical variables, assessment of cognitive status and QoL was performed.
  • After 1 year of participation in the trial, the participants were reassessed to determine if there had been any significant changes in cognition and general QoL.

Key results

  • 24 participants remained in the study at 1-year follow-up.
  • There were no significant changes in overall cognitive or functional adaptive status in the sample after 1 year.
  • QoL was reported by caregivers as significantly improved (P<.05 with a mean increase of points in overall qolce score.>